Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $36.48M
• Dividend Yield: N/A
• Average Volume (3M): 371.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.87
• Revenue Growth: 69.65%
• EPS Growth: 27.98%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 47,903,214
• 10 Day Avg. Volume: 162,100
• 30 Day Avg. Volume: 371,546
• PEG Ratio: -0.09
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.68
• Enterprise Value/Market Cap: -0.57
• Enterprise Value/Revenue: -0.42
• Enterprise Value/Gross Profit: 147.03
• Enterprise Value/Ebitda: 0.07
• 1Y Price Target: $4.00
• Price Target Upside: 426.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $1.00 ▲(31.58%Upside)

The overall score is significantly impacted by the company's weak financial performance and poor technical indicators, both reflecting ongoing challenges in revenue generation and profitability. Valuation metrics further underscore the company's struggles, with a negative P/E ratio and absence of dividends. Improvement in financial health and market sentiment is critical for a positive outlook.

Positive Factors

Clinical Progress

The company's pivot into inflammatory bowel disease (IBD) is seen as an underappreciated opportunity, with the lead program SL-325 representing a first-in-class approach with the potential to improve upon related, clinically-validated, TL1A targeting programs.

Financial Performance

The announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).

Preclinical Data

Preclinical results demonstrated SL-325 safety and feasibility of maintenance dosing, with a lead DR3 bispecific candidate nomination expected later this year.

Negative Factors

Early Stage Pipeline

The early stage of the company pipeline and a lack of near-term value drivers lead to maintaining a Hold Rating for Shattuck.

Operational Funding

Management expects the company's $60.9 million to fund operations into 2027, beyond results from its Phase 1 clinical trial of SL-325.

Research and Development Costs

Shattuck released its Q1 financials, including R&D expenses of $9.9MM and SG&A expenses of $4.5MM, leading to Q1 net losses of $13.7MM.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs (STTK) is a clinical-stage biotechnology company that focuses on developing novel therapeutics for the treatment of cancer and autoimmune diseases. The company specializes in its proprietary ARC (Agonist Redirected Checkpoint) platform, which is designed to create dual-function fusion proteins that modulate immune responses. Shattuck Labs operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs through innovative biological therapies.

How the Company Makes Money

Shattuck Labs makes money primarily through the development and eventual commercialization of its therapeutic products. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties. Additionally, as its therapies progress through clinical trials and receive regulatory approval, Shattuck Labs anticipates earning revenue from product sales. The company's ability to secure funding through investments and grants also supports its research and development activities, contributing to its financial stability.

Shattuck Labs Financial Statement Overview

Summary

Significant financial challenges with declining revenues, negative profitability, and operational inefficiencies. Despite a strong cash position, reliance on external financing is high. Continued focus on revenue growth and cost management is essential.

Income Statement

The company shows a significant decline in revenue growth over the years, with TTM revenue at $19.1 million compared to $30 million in 2021. Gross profit margin is negative, indicating high operating costs. Net profit margin remains negative, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and a lack of profitability.

Balance Sheet

The debt-to-equity ratio is low due to minimal debt, which is a positive aspect. However, the equity ratio has decreased over time, indicating a decline in financial stability. Return on equity is negative, reflecting persistent losses. The company maintains a strong cash position, although total assets have decreased, indicating potential liquidity concerns.

Cash Flow

The operating cash flow to net income ratio is negative, reflecting cash outflows from operations. Free cash flow has improved slightly but remains negative, indicating an inability to generate sufficient cash to cover expenses. Positive financing cash flow suggests reliance on external funding to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.72M	1.66M	652.00K	30.02M	9.93M
Gross Profit	5.72M	-2.38M	-2.72M	28.64M	-27.55M
EBITDA	-76.74M	-87.92M	-100.26M	-43.89M	-36.31M
Net Income	-75.41M	-87.30M	-101.94M	-44.35M	-35.44M
Balance Sheet
Total Assets	91.05M	159.56M	205.32M	298.58M	348.99M
Cash, Cash Equivalents and Short-Term Investments	72.99M	130.63M	161.28M	268.80M	335.45M
Total Debt	3.41M	4.20M	4.20M	0.00	0.00
Total Liabilities	11.42M	14.86M	29.17M	26.80M	39.13M
Stockholders Equity	79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow
Free Cash Flow	-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
Operating Cash Flow	-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
Investing Cash Flow	-8.51M	110.86M	49.44M	-10.44M	-146.32M
Financing Cash Flow	787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.94, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.35 is Neutral, neither overbought nor oversold. The STOCH value of 29.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LVTX	58 Neutral	$38.67M	―	-73.11%	―	-60.20%	3.85%
XLO	54 Neutral	$36.25M	―	-297.84%	―	―	53.92%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
STTK	42 Neutral	$36.48M	―	-71.90%	―	69.65%	27.98%
PYPD	41 Neutral	$35.67M	―	-853.05%	―	―	34.97%
ACRV	36 Underperform	$41.70M	―	-62.41%	―	―	10.84%

Shattuck Labs Corporate Events

Shattuck Labs Elects Directors, Approves Auditor at Meeting

On July 10, 2025, Shattuck Labs, Inc. held its Annual Meeting of Stockholders where all director nominees were elected and the proposal to ratify KPMG LLP as the independent auditor was approved. The meeting involved voting on the election of Class II Director Nominees and the ratification of KPMG LLP, reflecting shareholder support for the company’s governance and financial oversight.

The most recent analyst rating on (STTK) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Shattuck Labs stock, see the STTK Stock Forecast page.